Compound Detail
CHEMBL1713
CHLORPROMAZINE HYDROCHLORIDE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
7
Targets
26
Activities
3
Assay Types
4
PK Parameters
20
Publications
17
Known Names
2
Mechanisms
Molecular Properties
318.9
MW (Da)
4.89
ALogP
3
HBA
0
HBD
6.5
PSA (Ų)
0.79
QED
0
Ro5 Violations
4
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1957 |
| Availability | Prescription |
| Chirality | Achiral |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Serotonin 2a (5-HT2a) receptor antagonist | ANTAGONIST | 5-hydroxytryptamine receptor 2A | ✓ | ✓ |
| D2-like dopamine receptor antagonist | ANTAGONIST | D2-like dopamine receptor | ✓ | ✓ |
Drug Warnings
Black Box Warning
General Warning
Activity Summary
IC50 22 meas. best 7.75
EC50 2 meas. best 5.25
Ki 2 meas. best 8.52
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| D(2) dopamine receptor CHEMBL217 | Ki | 8.52 | 8.52 | 3.0 | 1 |
| D(2) dopamine receptor CHEMBL217 | IC50 | 7.75 | 7.75 | 18.0 | 1 |
| 5-hydroxytryptamine receptor 1A CHEMBL214 | Ki | 6.17 | 6.17 | 673.0 | 1 |
| SARS-CoV-2 CHEMBL4303835 | IC50 | 5.5 | 5.445 | 3140.0 | 2 |
| Plasmodium falciparum CHEMBL364 | IC50 | 5.4 | 5.1714 | 3981.1 | 7 |
| Unchecked CHEMBL612545 | EC50 | 5.25 | 5.08 | 5640.0 | 2 |
| Ishikawa CHEMBL614649 | IC50 | 4.66 | 4.66 | 21960.0 | 1 |
| Unchecked CHEMBL612545 | IC50 | 4.5 | 4.2863 | 31780.0 | 8 |
| KLE CHEMBL2366239 | IC50 | 4.46 | 4.46 | 35010.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| CL | 52.3 | mL.min-1.kg-1 | Homo sapiens |
| CL | 723.9 | mL.min-1.kg-1 | Mus musculus |
| T1/2 | 0.3967 | hr | Homo sapiens |
| T1/2 | 0.1267 | hr | Mus musculus |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| - | 10.6019/CHEMBL5303300 | U2OS | 304 |
| - | 10.6019/CHEMBL5303300 | Fibroblast | 304 |
| - | 10.6019/CHEMBL5303300 | HEK-293T | 304 |
| - | 10.6019/CHEMBL5303304 | HEK-293T | 9 |
| - | 10.1101/2020.03.25.008482 | SARS-CoV | 9 |
| - | 10.6019/CHEMBL5303304 | U2OS | 9 |
| 39082833 | 10.1021/acs.jmedchem.4c00638 | ADMET | 7 |
| 19734910 | 10.1038/nchembio.215 | Plasmodium falciparum | 7 |
| - | 10.6019/CHEMBL5303304 | Fibroblast | 5 |
| 8097538 | 10.1021/jm00060a015 | Mus musculus | 4 |
| - | 10.1101/2020.03.25.008482 | SARS-CoV-2 | 3 |
| 20426472 | 10.1021/jm100254w | No relevant target | 2 |
| - | 10.1101/2020.03.25.008482 | ADMET | 2 |
| - | 10.1101/2020.03.25.008482 | Vero C1008 | 2 |
| - | 10.6019/CHEMBL4495565 | SARS-CoV-2 | 2 |
| - | 10.6019/CHEMBL4808148 | Histone deacetylase 6 | 2 |
| 20426472 | 10.1021/jm100254w | Cruzipain | 2 |
| 8097538 | 10.1021/jm00060a015 | D(2) dopamine receptor | 2 |
| 17407813 | 10.1016/j.bmcl.2007.03.064 | 5-hydroxytryptamine receptor 2C | 1 |
| - | 10.6019/CHEMBL5608109 | Hepatocyte spheroids | 1 |
Data from ChEMBL 36 via Core Engine